AtlantiCare
en Español
 
AboutHealth ServicesHealth ConditionsLocationsEvents & CoursesCommunityWays of Giving
  Search  
 
Health News
Today's Headlines
Health Alerts
Health News Feature
Future of Medicine
Health Observances
Product Recalls
Health Library
Illnesses & Conditions
Drug Guide
FDA Drug Approvals
Medical Tests
Self-Help Resources
Complementary Medicine
Medline Search
Health Topics
Allergies
Asthma
Back Pain
Cancer
Caregiver
Depression
Diabetes
GERD
Heart
Kidney
Men's Health
Orthopedic
Parenting
Patient Safety
Pregnancy
Senior
Stress
Stroke
Weight Mgmt
Women's Health
Healthy Living
Fitness
Nutrition
Mind & Body
Family & Home
Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

First Generic Versions of Depakote Approved


To treat seizures, migraines, and bipolar disorder

TUESDAY, July 29 (HealthDay News) -- The first generic versions of Depakote (divalproex sodium) have been approved by the U.S. Food and Drug Administration to treat epileptic seizures, migraine headaches and bipolar disorder, the agency said Tuesday.

Eight firms were granted license to produce generic versions of the brand-name drug made by Abbott Laboratories. The generics will have the same label warnings as the brand-name medication, including cautions about increased risk of severe liver damage, inflamed pancreas, and neural tube birth defects.

"Generic drugs undergo a rigorous scientific review to ensure that they will provide the patient with the same amount of high quality, safe and effective drug as the name brand product," Gary Buehler, director of the FDA's Office of Generic Drugs, said in an agency news release.

More information

To learn more about this drug, also called valproic acid, visit the U.S. government's MedlinePlus site.

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay
 
 
Notice of Privacy Practices | | Disclaimer    © 2006 AtlantiCare AtlantiCare Access
 

  Powered by HEALTHvision